ArticleFrontiers in immunology2025
LST1: a novel biomarker for efferocytosis in the co-occurrence of type 2 diabetes mellitus and clear cell renal cell carcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The rising global incidence of clear cell renal cell carcinoma (ccRCC) often coincides with metabolic disorders like type 2 diabetes mellitus (T2DM). However, the association between these two conditions remains unclear. This study aimed to identify common molecular pathways and novel biomarkers for the comorbidity of T2DM and ccRCC. Methods: Utilizing single-cell transcriptomic datasets from the GEO public database, this study identified heterogeneous cell characteristics and core subpopulations in T2DM and ccRCC. Immune infiltration was assessed using the GSEA algorithm, and a prognostic model was optimized through machine learning algorithms. Key genes were pinpointed in conjunction with the optimal model's score. Subsequently, Results: Single-cell sequencing analysis revealed that efferocytosis was notably active in dead cell clearance in T2DM. In ccRCC, macrophages regulated efferocytosis to facilitate antigen presentation, modulate inflammation, and promote intercellular communication. Integrating machine learning and transcriptome analysis, we identified LST1 as a pivotal regulatory gene in both T2DM and ccRCC (AUC> 0.745). This result suggests that LST1 is involved in regulating macrophage-mediated efferocytosis and immune communication. Analysis of immune infiltration suggests that LST1-mediated efferocytosis may influence ccRCC susceptibility or disease progression by sustaining immune signaling activation and disrupting regulatory balance, potentially stemming from early inflammation in T2DM. Validation through Conclusion: This study initially identified LST1 as a pivotal regulatory factor in the co-occurrence of T2DM and ccRCC, emphasizing its essential involvement in the immune interaction within the hyperglycemia-induced microenvironment of ccRCC. These results not only elucidated the immunomodulatory role of LST1 in individual diseases but also delineated an immunological continuum bridging diverse conditions, providing a novel framework for investigating the immune pathways implicated in the concurrent presence of diabetes and malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.